Nina Farrokhnia1, Henrik Benoni2, Lana Ghanipour1, Peter H Cashin1. 1. Department of Surgical Sciences, Section of Colorectal Surgery, Uppsala University, Uppsala, Sweden. 2. Department of Surgical Sciences, Section of Transplantation Surgery, Uppsala University, Uppsala, Sweden.
Abstract
Background: Few studies on long-term survival have been published since the new updated pseudomyxoma peritonei (PMP) classification was published in 2016. The aim was to investigate long-term survival according to the Peritoneal Surface Oncology Group International (PSOGI) classification and compare prognostic factors. Methods: From Uppsala University Hospital, consecutive patients referred for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) from 2004 to 2017 with peritoneal disease from non-carcinoid mucinous epithelial appendiceal neoplasms were included in the study. The peritoneal disease was divided into four groups: mucin only, low-grade mucinous carcinoma peritonei (MCP-1), high-grade (MCP-2), and high-grade with signet ring cells (MCP-3). Survival curves were rendered, and prognostic factors were compared. Results: The study included 223 patients: 36 with mucin only, 112 with MCP-1, 70 with MCP-2, and 5 with MCP-3. Thirty-eight patients had a palliative debulking or open/close procedure. The 5- and 10-year overall survival was 97% and 97% for mucin only, 83% and 70% for MCP-1, 69% and 49% for MCP-2, with no patients still under follow-up after 5 years in the MCP-3 group. In a multivariable analysis, completeness of cytoreduction (CC) score 2-3 and PSOGI class MCP-3 were significantly associated with lower survival. The 5-year overall survival in the palliative setting was 40% vs. 44% (MCP-1 vs. MCP-2, P>0.05) with median survival 51 vs. 53 months, respectively. Conclusions: The PSOGI classification of PMP provides a solid differentiation of prognostic groups after CRS/HIPEC treatment, but not in the palliative setting. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Background: Few studies on long-term survival have been published since the new updated pseudomyxoma peritonei (PMP) classification was published in 2016. The aim was to investigate long-term survival according to the Peritoneal Surface Oncology Group International (PSOGI) classification and compare prognostic factors. Methods: From Uppsala University Hospital, consecutive patients referred for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) from 2004 to 2017 with peritoneal disease from non-carcinoid mucinous epithelial appendiceal neoplasms were included in the study. The peritoneal disease was divided into four groups: mucin only, low-grade mucinous carcinoma peritonei (MCP-1), high-grade (MCP-2), and high-grade with signet ring cells (MCP-3). Survival curves were rendered, and prognostic factors were compared. Results: The study included 223 patients: 36 with mucin only, 112 with MCP-1, 70 with MCP-2, and 5 with MCP-3. Thirty-eight patients had a palliative debulking or open/close procedure. The 5- and 10-year overall survival was 97% and 97% for mucin only, 83% and 70% for MCP-1, 69% and 49% for MCP-2, with no patients still under follow-up after 5 years in the MCP-3 group. In a multivariable analysis, completeness of cytoreduction (CC) score 2-3 and PSOGI class MCP-3 were significantly associated with lower survival. The 5-year overall survival in the palliative setting was 40% vs. 44% (MCP-1 vs. MCP-2, P>0.05) with median survival 51 vs. 53 months, respectively. Conclusions: The PSOGI classification of PMP provides a solid differentiation of prognostic groups after CRS/HIPEC treatment, but not in the palliative setting. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Jong Lyul Lee; Meejeong Kim; Jihun Kim; Chan Wook Kim; Ye Jin Ha; Seon-Young Kim; Dong-Hyung Cho; Jin Cheon Kim Journal: Asian J Surg Date: 2021-02-20 Impact factor: 2.767
Authors: Norman J Carr; Thomas D Cecil; Faheez Mohamed; Leslie H Sobin; Paul H Sugarbaker; Santiago González-Moreno; Panos Taflampas; Sara Chapman; Brendan J Moran Journal: Am J Surg Pathol Date: 2016-01 Impact factor: 6.394
Authors: Haroon A Choudry; Reetesh K Pai; Yongli Shuai; Lekshmi Ramalingam; Heather L Jones; James F Pingpank; Steven S Ahrendt; Matthew P Holtzman; Amer H Zureikat; Herbert J Zeh; David L Bartlett Journal: Ann Surg Oncol Date: 2017-11-06 Impact factor: 5.344
Authors: T Evans; O Aziz; B Chakrabarty; M S Wilson; L Malcomson; C Lavelle; S T O'Dwyer Journal: Eur J Surg Oncol Date: 2020-10-16 Impact factor: 4.424
Authors: J-B Delhorme; F Severac; G Averous; O Glehen; G Passot; N Bakrin; F Marchal; M Pocard; R Lo Dico; C Eveno; S Carrere; O Sgarbura; F Quenet; G Ferron; D Goéré; C Brigand Journal: Br J Surg Date: 2018-02-07 Impact factor: 6.939